ATE375804T1 - Ribavirin-enthaltende vakzine - Google Patents

Ribavirin-enthaltende vakzine

Info

Publication number
ATE375804T1
ATE375804T1 AT01972379T AT01972379T ATE375804T1 AT E375804 T1 ATE375804 T1 AT E375804T1 AT 01972379 T AT01972379 T AT 01972379T AT 01972379 T AT01972379 T AT 01972379T AT E375804 T1 ATE375804 T1 AT E375804T1
Authority
AT
Austria
Prior art keywords
ribavirin
antigen
disclosed
containing vaccines
vaccines
Prior art date
Application number
AT01972379T
Other languages
German (de)
English (en)
Inventor
Matti Sallberg
Catharina Hultgren
Original Assignee
Tripep Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripep Ab filed Critical Tripep Ab
Application granted granted Critical
Publication of ATE375804T1 publication Critical patent/ATE375804T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01972379T 2000-08-17 2001-08-15 Ribavirin-enthaltende vakzine ATE375804T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22576700P 2000-08-17 2000-08-17
US22917500P 2000-08-29 2000-08-29
US70554700A 2000-11-03 2000-11-03

Publications (1)

Publication Number Publication Date
ATE375804T1 true ATE375804T1 (de) 2007-11-15

Family

ID=27397520

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01972379T ATE375804T1 (de) 2000-08-17 2001-08-15 Ribavirin-enthaltende vakzine
AT07020248T ATE517184T1 (de) 2000-08-17 2001-08-15 Hcv ns3/4a kodierende nukleinsäure

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07020248T ATE517184T1 (de) 2000-08-17 2001-08-15 Hcv ns3/4a kodierende nukleinsäure

Country Status (12)

Country Link
US (1) US6960569B2 (enExample)
EP (3) EP2332574A1 (enExample)
JP (1) JP5175417B2 (enExample)
KR (2) KR20070114209A (enExample)
CN (1) CN100400101C (enExample)
AT (2) ATE375804T1 (enExample)
AU (4) AU2001292151B2 (enExample)
CA (1) CA2419418A1 (enExample)
DE (1) DE60130998T2 (enExample)
ES (1) ES2296803T3 (enExample)
PL (1) PL360990A1 (enExample)
WO (2) WO2002014362A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100400101C (zh) * 2000-08-17 2008-07-09 特里帕普股份公司 包含病毒唑的疫苗及其使用方法
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
JP2005509591A (ja) * 2001-06-15 2005-04-14 リバファーム・インコーポレイテッド ヌクレオシドワクチンアジュバント
EP1539941A4 (en) * 2002-08-27 2006-11-29 ADZYMES AND THEIR USES
KR20050086843A (ko) * 2002-11-26 2005-08-30 트리펩 아베 증강인자 성분으로서의 ｃ형 간염 바이러스 비구조 단백질4ａ(ｎｓ4ａ)
US7419912B2 (en) 2004-04-01 2008-09-02 Cree, Inc. Laser patterning of light emitting devices
DE602005002673T2 (de) * 2004-04-29 2008-07-24 F. Hoffmann-La Roche Ag Nukleotidsequenzvariation im Gen NS5A als Marker
DE602005022463D1 (de) * 2004-09-29 2010-09-02 Univ Tulane Inhibitoren des hepatitis-c-virus
AU2012200012B8 (en) * 2004-09-29 2014-05-01 The Administrators Of The Tulane Educational Fund Inhibitors of hepatitis C virus
EP1888751A2 (en) * 2005-05-25 2008-02-20 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
WO2008004992A2 (en) * 2005-05-25 2008-01-10 Tripep Ab Transdermal formulations containing hepatitis c virus immunogens and an ethoxylated oil
PT1949913E (pt) * 2005-10-07 2010-08-24 Proyecto Biomedicina Cima Sl Associação imunoestimuladora para a profilaxia e o tratamento da hepatite c
ES2334472B1 (es) * 2006-06-09 2011-01-21 Proyecto De Biomedicina Cima, S.L. Combinacion inmunoestimuladora para profilaxis y tratamiento de hepatitis c.
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
WO2009079834A1 (en) * 2007-12-18 2009-07-02 Peking University People's Hospital An anti-hcv vaccine and preparation methods and uses thereof
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
CN108148121B (zh) * 2018-03-06 2021-07-09 中美赛尔生物科技(广东)有限公司 丙型肝炎病毒抗原多肽组合物以及丙型肝炎病毒疫苗

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2933693A (en) 1957-05-03 1960-04-19 Lyle R Battersby Sensitivity control circuit
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4818540A (en) 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
WO1989004669A1 (en) * 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
US5679342A (en) 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
US5712088A (en) 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5714596A (en) 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5683864A (en) 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5968775A (en) 1987-11-18 1999-10-19 Chiron Corporation Hepatitis C virus infected cell systems
US4950647A (en) 1988-10-04 1990-08-21 Nucleic Acid Research Institute T cell immunopotentiator
HUT54896A (en) 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6027729A (en) 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
WO1990014436A1 (en) 1989-05-18 1990-11-29 Chiron Corporation Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
ATE161041T1 (de) 1989-08-25 1997-12-15 Chiron Corp Verfahren zur hcv-züchtung in zell-linien aus b- oder t-lymphozyten
WO1991004262A1 (en) * 1989-09-15 1991-04-04 National Institute Of Health Of Japan New hcv isolates
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
US5712087A (en) 1990-04-04 1998-01-27 Chiron Corporation Immunoassays for anti-HCV antibodies employing combinations of hepatitis C virus (HCV) antigens
AU7675491A (en) 1990-04-04 1991-10-30 Chiron Corporation Hepatitis c virus protease
US6194140B1 (en) 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
KR100206150B1 (ko) 1990-04-04 1999-07-01 로버트 피. 블랙버언 항-에이치씨브이 항체에 대한 면역분석용 씨형 간염 바이러스(에이치디브이)항원의 조합체
DE69126617T2 (de) 1990-08-10 1997-10-02 Chiron Corp Nanbv diagnostik: für die untersuchung auf hepatitis c verwendbare polynukleotide
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
US5710008B1 (en) 1990-10-12 1999-09-07 Spectral Diagnostics Inc Method and device for diagnosing and distinguishing chest pain in early onset thereof
CA2027434C (en) 1990-10-12 1999-01-05 George Jackowski Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US6274148B1 (en) 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
DE69131882T3 (de) 1990-11-08 2007-05-24 Novartis Vaccines and Diagnostics, Inc., Emeryville Asiloglycoproteine des hepatitis c-virus
DK0562025T3 (da) 1990-12-06 2001-06-18 Affymetrix Inc Forbindelser og deres anvendelse i en binær syntesestrategi
US6190864B1 (en) 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
RU2155228C2 (ru) 1991-05-08 2000-08-27 Чирон Корпорейшн Hcv геномные последовательности для диагностических и терапевтических целей
FR2677372B1 (fr) * 1991-06-06 1994-11-10 Pasteur Institut Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques.
KR0185426B1 (ko) 1991-06-24 1999-04-01 로버트 피. 블랙버언 씨형 간염 바이러스 폴리펩티드
DK0608261T3 (da) 1991-09-13 2003-03-17 Chiron Corp Sammensætninger med immunreaktivt hepatitis C virus polypeptid
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5795714A (en) 1992-11-06 1998-08-18 Trustees Of Boston University Method for replicating an array of nucleic acid probes
DE4239311C2 (de) 1992-11-23 1996-04-18 Guehring Joerg Dr Bohrer, insbesondere Spitzbohrwerkzeug mit austauschbarem Schneideinsatz
ES2249760T3 (es) 1993-01-26 2006-04-01 The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) Composiciones y procedimientos de administracion de materias geneticas.
US6762024B2 (en) 1993-04-27 2004-07-13 Innogenetics, S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
DK0789590T3 (da) 1994-09-23 2002-11-04 Zonagen Inc Chitosaninduceret immunforstærkning
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
DE69526973T3 (de) 1994-10-21 2010-01-07 Innogenetics N.V. Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel
FR2730935A1 (fr) 1994-12-21 1996-08-30 Vacsyn Sa Vaccin presentant une immunogenicite accrue
US5932556A (en) 1995-09-17 1999-08-03 Tam; Robert C Methods and compositions for regulation of CD28 expression
WO1996028162A1 (en) 1995-03-14 1996-09-19 University Of Medicine & Dentistry Of New Jersey New drug combination for the treatment of viral diseases
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6150337A (en) 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
CZ293584B6 (cs) * 1996-01-23 2004-06-16 Icn Pharmaceuticals Prostředek pro modulaci exprese lymfokinů
WO1997029212A1 (en) 1996-02-08 1997-08-14 Affymetrix, Inc. Chip-based speciation and phenotypic characterization of microorganisms
AU735440B2 (en) 1996-02-09 2001-07-05 Cornell Research Foundation Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
CA2257137A1 (en) 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
SK284054B6 (sk) 1996-10-16 2004-08-03 Icn Pharmaceuticals, Inc. Substituované triazolové nukleozidy, farmaceutický prostriedok s ich obsahom a ich použitie
AU727177B2 (en) 1996-10-16 2000-12-07 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
WO1998030223A1 (en) 1997-01-17 1998-07-16 Icn Pharmaceuticals, Inc. Cytokine related treatments of disease
EE9900343A (et) 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
WO1998037180A2 (en) 1997-02-22 1998-08-27 Abbott Laboratories Hcv fusion protease and polynucleotide encoding same
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
US6211338B1 (en) * 1997-11-28 2001-04-03 Schering Corporation Single-chain recombinant complexes of hepatitis C virus NS3 protease and NS4A cofactor peptide
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
AU751362B2 (en) * 1998-04-17 2002-08-15 Innogenetics N.V. Improved immunodiagnostic assays using reducing agents
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
CA2357735A1 (en) 1999-01-29 2000-08-03 Icn Pharmaceuticals, Inc. Modulation of immune response by ribavirin
US20020187945A1 (en) 1999-01-29 2002-12-12 Robert Tam Modulation of immune response by ribavirin
DE60036881T2 (de) * 1999-11-24 2008-07-10 Novartis Vaccines and Diagnostics, Inc., Emeryville Neues nichtstrukturelles hcv-polypeptid
BRPI0111731C1 (pt) * 2000-06-15 2021-07-27 Chiron Corp suporte sólido de imunoensaio, métodos de detecção de infecção pelo vírus da hepatite c (hcv) em uma amostra biológica, e de produção de um suporte sólido de imunoensaio, e, kit de teste de imunodiagnóstico
CN100400101C (zh) 2000-08-17 2008-07-09 特里帕普股份公司 包含病毒唑的疫苗及其使用方法
JP4475561B2 (ja) 2001-10-11 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション Ｃ型肝炎ウイルスワクチン
KR20140137679A (ko) 2013-05-23 2014-12-03 삼성전자주식회사 카드 소켓 장치
KR102894414B1 (ko) 2019-08-14 2025-12-02 삼성전자주식회사 무선 통신 시스템에서 rrm 측정을 수행하는 방법 및 단말

Also Published As

Publication number Publication date
WO2002013855A3 (en) 2003-01-09
WO2002013855A2 (en) 2002-02-21
WO2002014362A3 (en) 2003-11-13
CN100400101C (zh) 2008-07-09
PL360990A1 (en) 2004-09-20
EP2332574A1 (en) 2011-06-15
CN1469755A (zh) 2004-01-21
CA2419418A1 (en) 2002-02-21
AU2006203358B2 (en) 2008-07-17
ATE517184T1 (de) 2011-08-15
KR20070114209A (ko) 2007-11-29
DE60130998T2 (de) 2008-07-17
US20040092730A1 (en) 2004-05-13
AU2001292151B2 (en) 2006-05-04
EP1311289A2 (en) 2003-05-21
AU2001292151C1 (en) 2002-02-25
EP1311289B1 (en) 2007-10-17
JP5175417B2 (ja) 2013-04-03
US6960569B2 (en) 2005-11-01
AU2006203358A1 (en) 2006-08-31
EP1947185B1 (en) 2011-07-20
ES2296803T3 (es) 2008-05-01
DE60130998D1 (de) 2007-11-29
JP2004506018A (ja) 2004-02-26
KR100801123B1 (ko) 2008-02-05
EP1947185A1 (en) 2008-07-23
WO2002014362A2 (en) 2002-02-21
AU2001290178A1 (en) 2002-02-25
AU9215101A (en) 2002-02-25
KR20030024876A (ko) 2003-03-26

Similar Documents

Publication Publication Date Title
DE60130998D1 (de) Ribavirin-enthaltende vakzine
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
DK1090033T4 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
ATE309268T1 (de) Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens
ATE501726T1 (de) Zusammensetzung mit immunogenen mikroteilchen
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
DK1296711T3 (da) HPV-E7 til behandling af humant papillomavirus
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
EA200401405A1 (ru) Модифицированный осповакцинный вирус анкара для вакцинации новорожденных
DE60117978D1 (de) Modifizierung des hepatitis b kernantigens
DE60039715D1 (de) Hcv-impfstoff zusammensetzungen
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
EP1256348A4 (en) REMEDIES AGAINST HEPATITIS
WO2002062959A3 (en) Hepatitis b virus treatment
ATE310008T1 (de) Immunologische adjuvans verbindungen
EA200301151A1 (ru) Вакцина против натуральной оспы
WO2004043404A3 (en) Process for designing inhibitors of influenza virus non-structural protein 1
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
WO2002015664A3 (en) Methods of preventing or treating west nile virus and other infections
DE602006014720D1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
ATE476189T1 (de) Dialysierter leukozytenextrakt zur behandlung von infektionskrankheiten bei tieren
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
BR0101523A (pt) Pestivìrus, vacina, e, processos para imunizarcontra doença induzida por pestivìrus e parafabricar uma vacina para a proteção de um animalcontra um pestivìrus
EA200400534A1 (ru) Стимуляция тимозином генетической иммунизации
ATE467424T1 (de) Escape-mutanten des newcastle-disease-virus als marker-vakzine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1311289

Country of ref document: EP